Vildagliptin (Galvus®) 50 mg tablets
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000878
English
Authors' recommendations:
Vildagliptin (Galvus®) 50 mg tablets are recommended as an option for use within NHS Wales for the treatment of type 2 diabetes in patients with moderate or severe renal impairment.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/Documents/371/vildagliptin%20%28Galvus%29%20FAR.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Dipeptidyl-Peptidase IV Inhibitors
- Diabetes Mellitus, Type 2
- Blood Glucose
- Pyrrolidines
- Nitriles
- Adamantane
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.